Issued 2026-08-13 at $8.87 · now $9.01 (2026-08-13, +1.6% since)
Based on its own history, a month from the 2026-08-13 close, ARVN has typically landed between $6.55 and $11.49 — a range of −26.1% to +29.5% from the issuance price $8.87.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,957 overlapping 1 month windows · 2018-09-27 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($8.87) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where ARVN has typically landed a month from the 2026-08-13 close of $8.87 — the range is history, not a prediction.
- now $9.01 (+1.6%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.61 (-3.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $7.65–$9.56
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.55–$11.49
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-03-07 | −65.2% | −65.2% | +0.0% |
| 2025-03-10 | −64.7% | −64.7% | +0.0% |
| 2025-03-06 | −63.7% | −63.7% | +1.2% |
| 3 best | |||
| 2020-11-23 | +251.2% | +0.0% | +251.2% |
| 2020-11-30 | +251.0% | +0.0% | +251.0% |
| 2020-11-24 | +245.9% | −1.7% | +245.9% |
1,957 overlapping windows · 2018-09-27 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2027-11-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation (source, as of 2026-08-14)
- 2031-03-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.